Key Features of Economic Models Used in Submissions to NICE in Dermatology Indications

Speaker(s)

Clemmet T1, Campbell K2, Basarir H2
1RTI Health Solutions, Manchester, LAN, UK, 2RTI Health Solutions, Manchester, UK

OBJECTIVES: To review the key features of economic models used in submissions to the National Institute for Health and Care Excellence (NICE) in dermatology indications.

METHODS: The NICE website was searched on 24 April 2024 to identify technology appraisals (TAs) reporting cost-effectiveness analyses in dermatology.

RESULTS: Searches identified 33 TAs, 9 of which were excluded (4 cost comparisons, 4 not dermatology, 1 in development). The remaining 24 TAs were included.

The structures of 13 (all psoriasis [PsO]) of these 24 models were based on the York Model (TA103), which comprises short-term decision-tree and long-term Markov components. Five of 24 had a similar structure to the York Model without explicit citation (3 atopic dermatitis [AD], 1 alopecia areata [AA], 1 prurigo nodularis). In these 18 models, response was based on condition-specific measures, and differences included the response definition, timing of response assessment, treatment sequencing, and short-term modelling approach. The remaining 6 of 24 used alternative structures: 2 were individual-level (hand eczema and urticaria) and 4 were cohort-level (2 hidradenitis suppurativa [HS], 1 AA, 1 AD) models.

Convergence Diagnosis and Output Analysis (CODA) was used to preserve the relationship between response covariates in probabilistic analyses in 10 TAs (8 PsO, 1 AD, 1 HS). Waning of treatment effect was implemented in 3 AD models. All but 1 (in AA, citing lack of quality-of-life improvement and unacceptable level of uncertainty around cost-effectiveness outcomes) of the included TAs received a recommendation. The endpoint and threshold used to define response were the main concerns of evidence assessment groups.

CONCLUSIONS: Economic models in 24 NICE submissions in dermatology were reviewed. Most models were based on or similar to the York Model. Almost half used CODA, and a minority implemented waning of treatment effect. Endpoints and their use were the primary concern. Recommendations were not related to the model features.

Code

EE503

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Sensory System Disorders (Ear, Eye, Dental, Skin)